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Evaluation of the Susceptibility Profiles, Genetic Similarity and Presence of qnr Gene
in Escherichia coli Resistant to Ciprofloxacin Isolated in Brazilian Hospitals
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Increasing quinolone resistance has been reported worldwide, mainly among clinical isolates of Escherichia coli.
The objectives of this study were to determine the susceptibility profile, the genetic relatedness, and the prevalence
of the qnr gene among ciprofloxacin-resistant Escherichia coli isolated from distinct Brazilian hospitals. A total of
144 ciprofloxacin-resistant Escherichia coli were isolated from 17 Brazilian hospitals between January/2002 and
June/2003. The antimicrobial susceptibility testing was performed by microdilution according to NCCLS. The
presence of the qnr gene was initially screened by colony blotting, and then confirmed by PCR followed by DNA
sequencing. Ninety-five urinary ciprofloxacin-resistant Escherichia coli were further selected for molecular typing
by pulsed-field gel electrophoresis (PFGE). Imipenem and meropenem showed the highest susceptibility rates
(100.0% for both compounds) followed by amikacin (91.0%) and piperacillin/tazobactan (84.8%). A single ciprofloxacin-
resistant Escherichia coli isolate was positive for qnr among the 144 ciprofloxacin-resistant Escherichia coli. Forty-
six PFGE patterns were observed among the 95 ciprofloxacin-resistant Escherichia coli type. This study shows that
therapeutic options are limited for treatment of ciprofloxacin-resistant Escherichia coli due to the presence of
additional mechanisms of antimicrobial resistance, such as ESBL production. The qnr gene was uncommon among
ciprofloxacin-resistant Escherichia coli clinical isolates, but its identification might indicate the emergence of this
mechanism of quinolone resistance in Brazil. The great genomic variability found among the ciprofloxacin-resistant
Escherichia coli highlights the importance of the appropriate use of quinolone to restrict the selection of resistant
isolates.
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Escherichia coli is a leading cause of nosocomial as
well as community-acquired infections, especially urinary
tract infections (UTI) [1,2]. Recent studies have shown a
considerable increase in the prevalence of resistance to
ciprofloxacin among clinical isolates of Escherichia coli
[3,4]. Although quinolone resistance generally results from
chromosomal mutation in gyrA and parC genes, recent
studies showed that low-level resistance can be also
plasmid mediated by the acquisition of the qnr gene
mediated by plasmid pMG252 [5-7]. This plasmid was first
report in 1998 in a Klebsiella pneumoniae clinical strain
isolated in 1994 at the University of Alabama at Birmingham
Medical Center [8], but has still not been detected among
isolates from South America.
The objectives of this study were to determine the
susceptibility profile, the genetic relatedness, and the frequency
of the qnr gene among ciprofloxacin-resistant Escherichia coli
(CR-EC) isolated from distinct Brazilian hospitals.
Materials and Methods
Participant Institutions
A total of seventeen medical centers participated in the
study. The centers were located throughout eight Brazilians
estates: Bahia (one center), Minas Gerais (two centers), Brasília
(one center), Ceará (two centers), Maranhão (one center),
Paraná (two centers), Rio Grande do Sul (one center), Santa
Catarina (one center) and São Paulo (six centers) (Figure 1).
Bacterial Isolates
The Brazilian hospitals were requested to send CR-EC
isolates to the coordinating laboratory. From January 2002 to
June 2003, a total of 144 clinical isolates of CR-EC were isolated
from the 17 hospital-based laboratories. Only one isolate per
patient was included in the study. The isolates were identified
at the participating institution by the routine methodology in
use at each laboratory. Confirmation of species identification
was performed by biochemical conventional methods if
necessary.
Antimicrobial Susceptibility
Antimicrobial susceptibility testing was performed using
the reference broth microdilution method as described by the
National Committee for Clinical Laboratory Standards (NCCLS
2003). The minimal inhibitory concentration (MIC) was defined
as the lowest antimicrobial concentration able to totally inhibit
bacterial growth. Quality control was performed by testing
Escherichia coli ATCC 25922, Pseudomonas aeruginosa
ATCC 27853 and Klebsiella pneumoniae ATCC 70603.
According to NCCLS criteria, MICs ≥ 2 µg/mL for
cefotaxime and/or ceftriaxone and/or ceftazidime and/or
aztreonam were considered as extended-spectrum β-lactamase
(ESBL) producers [9]. The ESBL phenotype was confirmed
by using the addition of clavulanic acid (Oxoid® Basingstoke,
England) according to manufacture recommendation.
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Screening for the qnr Gene in Clinical Strains EC-QR
All clinical strains of EC-QR were screened for the qnr
gene by the colony blotting and Southern hybridization
methods using the kit “Ready to go” (Amersham Pharmacia
Biotech Inc., New Jersey, EUA), in accordance with the
manufacture’s recommendations. The qnr probe was made
from plasmid pMG252 by PCR amplification with primers sense
5’ GATAAAGTTTTTCAGCAAGAGG 3’ and anti-sense 5’
ATCCAGATCGGCAAAGGTTA 3’.
PCR Detection of qnr Gene
The gene was amplified by using primers QP1 (5’
GATAAAGTTTTTCAGCA AGAGG 3’starting at the 12th qnr
nucleotide) and QP2 (5’ ATCCAGATCGGCAAA GGTTA 3’)
to produce a 593-bp product, as described by Jacoby et al.
[6]. PCR conditions were 94°C for 1 min, 57°C for 30 s, and
72°C for 1 min for 30 cycles.
Quality Control
The QnrA-producing Klebsiella pneumoniae pMG252 and
Escherichia coli ATCC 25922 were used as positive and
negative quality controls for hybridization and PCR
experiments, respectively.
Nucleotide Sequence of qnr Gene
Sequencing was performed using Big Dye terminator
version II (BigDye™ Terminators v2.0 – Cycle Sequencing
Kit – Applied biosystems-ABI PRISM®, California, EUA) and
in equipment an ABI PRISM 377 DNA Analyzer (Perkin Elmer®,
California, EUA) reading was performed. The nucleotide
sequence has been submitted to the GenBank database and
assigned accession number AM295981.
Evaluation of Genetic Similarity in CR-EC Isolates
CR-EC collected from urinary tract infections were selected
for molecular typing by Pulsed-field gel electrophoresis
(PFGE). From each medical center, a maximum of 10 CR-EC
isolates were included for analysis. Genomic DNA was
prepared for restriction fragments analysis as described by
Pfaller [10] and digested with SpeI restriction enzyme (New
England Biolab, Inc., Beverly, USA). PFGE was performed on
the CHEF DR III (Bio-Rad, Richmond, CA), under the following
conditions: 1% agarose, 13ºC, 200V for 23h. The obtained
fragments were analyzed according to the Pfaller criteria (1992)
[10].
Results
Among the 144 CR-EC, a total of 76.4% and 3.5% were
isolated, respectively, from patients with urinary tract
infections and bloodstream infections. The remaining isolates
(n=29) were recovered from peritoneal fluids, bronchoalveolar
wash, catheter tip and multiple abscesses. A total of 43% of all
CR-EC from urinary tract infections were collected from
outpatients, reflecting the increasing frequency of quinolone
resistance among community-acquired infections in the
Brazilian medical centers. Although data from the SENTRY
program in Latin America has already detected an increasing
frequency of CR-EC in this region, these data were collected
from hospitalized patients [1]. This high frequency of CR-EC
found in the present study contrasts with data from other
countries, such as the United States, where the prevalence of
quinolone resistance among UTI isolates ranges from 0.7% in
1996 to 2.5% in 2001 [2]. The current data may be related to the
increased use of quinolones for the treatment of community-
acquired infections, such as UTI and respiratory tract
infections in Brazil.
The antimicrobial activity and susceptibility profile of all
144 CR-EC is summarized in Table 1. The best coverage was
achieved by the tested carbapenems, imipenem and
meropenem (100.0%), followed by amikacin (91%) and
ceftazidime (91%), and piperacilin/tazobactan (84.8%). The
decreased susceptibility rates to cefoxitin (47.6%) may reflect
the presence of alternate resistance mechanisms, such as
alterations in outer membrane permeability, AmpC
hyperproduction [11,12] or the acquisition of plasmid-borne
genes mediating the expression of other class C β-lactamases
[13-15].
Based on the NCCLS/CLSI criteria, 22.9% (n=33) of the
CR-EC isolates collected between 2002 and 2003 could be
considered ESBL producers. The production of ESBL was
variable according to sex, age and infection origin, as shown
in Table 2. Although there was no difference in relation to sex
and infection origin, isolates recovered from patients older
than 60 years old presented an increased chance of  harboring
the ESBL phenotype (p=0,006). These data is in accordance
to a previous study by Eom at al. (2002) [16], where advanced
age was a risk factor associated with the acquisition of
quinolone-resistant E. coli among patients with UTI.
In this study, CR-EC harboring the ESBL phenotype could
be detected in most of participating medical centers in Brazil
(76.4%), indicating these multi-drug-resistant isolates are a
reality in many geographical regions within the country. This
increased ESBL production rate among CR-EC is worrisome,
since the treatment of these multi-drug-resistant isolates is
limited to the available carbapenems.
A total 144 CR-EC isolates were screened by colony
blotting and Southern hybridization method. Only one clinical
isolate yielded a hybridization signal with the qnr gene probe
as showed in the Figure 2. This isolate was sent by a hospital
in Porto Alegre, from an 80 year- old patient with urinary tract
infection. Among the tested antimicrobial agents, this sample
was resistant to ciprofloxacin, nalidixic acid, piperacillin/
tazobactam, and cefoxitin. The ESBL screening and
confirmatory tests were both negative for this specific sample.
The qnr gene was sought by PCR by using specific primers in
this strain, which was positive for screening test (Figure 3).
After performing the nucleotide sequencing, a sequence of
493 bp fragment was obtained, identical to those of the original
plasmid pMG252, as previously described by Jacoby et al. in
2003 [6].
Escherichia coli Resistant to Ciprofloxacin
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Table 1. Antimicrobial potency and spectrum for selected
antimicrobial agents tested against CR-EC isolates in 17
Brazilian laboratory-based hospitals
Antimicrobial agents µg/mL % Susceptibility
MIC50 MIC90
β-lactams
Aztreonam ≤1 >32 77.9
Ceftriaxone ≤1 >64 75.9
Ceftazidime ≤1 8 91.0
Cefoxitin 4 32 52.4
Cefepime ≤1 >32 80.0
Ampicillin/Sulbactam 32 >64 27.6
Piperacilin/Tazobactam ≤8 128 84.8
Carbapenems
Imipenem ≤0,25 ≤0,25 100.0
Meropenem ≤0,25 ≤0,25 100.0
Quinolones
Nalidix acid ≥32 >32 0.0
Gatifloxacin ≥8 ≥8 3.4
Aminoglycosides
Gentamicin ≤2 >16 65.7
Amikacin ≤8 16 91.0
Table 2. Demographic characteristics of the 33 ciprofloxacin-
resistant ESBL-producing E. coli isolates
                  ESBL producing (%)
Sex
Male 16 (48.5)
Female 17 (51.5)
Age a
≤ 1 2 (6.1)
2-12 1 (3.0)
13-60 8 (24.2)
>60 16 (48.5)
Infection origin
Community 5 (15.2)
Nosocomial 7 (21.2)
Indeterminated 21 (63.6)
a Age information was missing from 6 isolates.
Figure 1. The participating medical centers are marked on the
map with a circle signal.
Figure 2. Screening for the qnr gene by colony blotting
technique.
Figure 3. Detection of qnr gene by PCR. Line 1, Molecular
weight marker; Line 2, negative quality control strain (ATCC
25922 E. coli); Line 3, clinical isolate (13.52); Line 4, positive
quality control strain (pMG252 K. pneumoniae) and Line 5,
master-mix solution.
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Discussion
The current study identified, for the first time, the presence
of the qnr gene in a clinical isolate of E. coli from a city in
Brazil. This finding may reflect the ability and the possibility
of acquisition of this unusual genotype by Brazilian isolates
of E. coli. The low frequency of qnr gene isolation was also
described by other authors. After evaluating a total of 91 E.
coli isolates from the United States, Jacoby et al. (2003) [6]
could identify only one isolate harboring the qnr gene. In
China, a study by Wang et al. [7] also found a low prevalence
(8%) of this genotype among the high-level quinolone resistant
E. coli.
Similar PFGE profiles were detected among patients from
the same medical center, possibly indicating a patient-to-
patient transmission of resistant isolates. On the other hand,
a total of 46 distinct PFGE patterns were detected among the
95 CR-EC isolated from urinary tract infections, indicating an
elevated genetic diversity. Therefore, this increased frequency
of CR-EC may be associated with the selection of resistant E.
coli isolates from the patients’ own flora. These isolates may
be associated to the previous use of fluoroquinolones by the
patient, or by the ingestion of food products contaminated
with resistant pathogens. This last hypothesis was confirmed
by a study in Spain, which found an elevated number of
quinolone-resistant E. coli colonizing poultry and pork [3].
Additional PFGE studies are necessary to establish the
temporal and geographical distribution of these resistant
isolates, in order to determine the mode of dissemination.
Fluoroquinolone usage and prescription should be
restricted among community and hospitalized patients, mainly
among populations with an increased risk of developing this
resistance phenotype. Additional surveillance studies are
necessary to understand the dissemination of quinolone
resistance in Brazil, to help implementing appropriate control
measures, as well as to guide the adequate use of antimicrobial
agents in this geographic region.
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